Grants
Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount | Activity |
Investigator |
Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Pembrolizumab + Lenvatinib + Chemotherapy Induction Therapy Followed by Pembrolizumab + Lenvatinib Compared with… | Contract | $500.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Merck Sharp & Dohme Corp. | 02/2021 |
| Prospective Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Metastatic Colorectal Cancer | Contract | $99,034.20 | Clinical Trial | Aaron Scott | Cancer Center Division | Faeth Therapeutics, Inc. | 05/2022 |
| Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-Type, Left-Sided Colorectal Cancer | Contract | $127,173.74 | Clinical Trial | Aaron Scott | Cancer Center Division | Academic Gastrointestinal Cancer Consortium | 03/2020 |
| A Phase 2 Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers | Contract | $226,383.60 | Clinical Trial | Aaron Scott | Cancer Center Division | Apexigen | 04/2021 |
| A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naive, HER2-Positive G | Contract | $194,029.06 | Clinical Trial | Aaron Scott | Cancer Center Division | MacroGenics Inc | 07/2021 |
| A Phase 1a/B Study to Evaluate the Safety and Tolerability of Etc-1922159 in Advanced Solid Tumours | Contract | $364,303.75 | Clinical Trial | Aaron Scott | Cancer Center Division | PPD Investigator Services, LLC. | 01/2022 |
| A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcino | Contract | $337,055.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Incyte Corporation | 04/2021 |
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator Phase 2/3 study of Tucatinib in Combination with Trastuzumab, Ramucirumab, and Paclitaxel in Subjects with Previously Treated, Locally | Contract | $453,804.20 | Clinical Trial | Aaron Scott | Cancer Center Division | Seagen Inc. | 01/2021 |
| INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multi-center Trial With and Without APX005M, an Anti-CD40 Agonist | Contract | $70,892.00 | Clinical Trial | Aaron Scott | Cancer Center Division | University of Texas Southwestern Medical Center | 02/2022 |
| A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable.. | Contract | $171,440.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Incyte Corporation | 05/2020 |
| A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer | Contract | $299,953.80 | Clinical Trial | Aaron Scott | Cancer Center Division | G1 Therapeutics | 05/2021 |
| A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Sub | Contract | $557,729.00 | Clinical Trial | Aaron Scott | Cancer Center Division | Biosplice Therapeutics, Inc. | 04/2022 |
| A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab +/- Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metas | Contract | $404,272.70 | Clinical Trial | Aaron Scott | Cancer Center Division | Leap Therapeutics, Inc. | 10/2020 |
| A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction... | Contract | $105,851.40 | Clinical Trial | Aaron Wolfson | Sarver Heart Center | Cytokinetics, Incorporated | 09/2020 |
| A Phase II Trial of PET-Directed Therapy using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin Plus Nivolumab, Foll | Contract | $40,100.00 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Mayo Foundation for Medical Education and Research (Mayo Clinic) | 06/2020 |
| A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel.. | Contract | $327,830.00 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Covance, Incorporated | 01/2020 |
| An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | Contract | $323,960.68 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Pharmaceutical Research Associates | 04/2022 |
| Accuracy of Arthroscopic vs. Open Reduction of Ankle Syndesmosis Injuries | Contract | $5,000.00 | Research Training | Aditya Manoharan | Orthopaedic Surgery | Orthopaedic Research and Education Foundation | 04/2020 |
| A Randomized Controlled Trial to Improve Mother-Infant Synchrony Among Women with Childhood Adversity | Grant | $2,437,784.00 | Research | Aleeca Bell | College of Nursing | National Institute of Nursing Research | 09/2020 |
| A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-Resistant Prostate Cancer | Contract | $227,327.00 | Clinical Trial | Alejandro Recio Boiles | Cancer Center Division | Syneos Health | 04/2021 |
| A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies | Contract | $468,451.00 | Clinical Trial | Alejandro Recio Boiles | Cancer Center Division | Atreca, Inc. | 10/2020 |
| A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma | Contract | $1,354,476.50 | Clinical Trial | Alejandro Recio Boiles | Cancer Center Division | Mirati Therapeutics, Inc. | 03/2021 |
| Thrombocyte Regulation of Anti-Parasite Immunity | Grant | $767,500.00 | Research | Alfred Bothwell | Immunobiology | National Institute of Allergy and Infectious Disease | 02/2022 |
| 2020-2021 Danone North America Gut Microbiome, Yogurt and Probiotics Fellowship Grant | Grant | $25,000.00 | Research | Alice Solomon | Physiology | Danone Institute North America | 07/2021 |
| Hormonal Response to Infant Caregiving: A Novel Strategy to Break the Opioid Relapse Cycle During The Postpartum Period | Grant | $2,302,500.00 | Research | Alicia Allen | Family and Community Medicine | Eunice Kennedy Shriver National Institute of Child Health and Human Development | 09/2020 |